Indapamide
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Indapamide
Indapamide: Known uses and market status in Australia
Summary
The TxGNN deep-learning model has no candidate indication for Indapamide with a score of 0.99 or higher, so there is currently no new predicted indication. The drug’s recorded uses are listed below. They come from existing records and are not model candidates.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (no model candidate scored 0.99 or higher) |
| Known uses recorded for this drug | 3 |
| Evidence level | Not applicable |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
Known uses recorded for this drug
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| none | none |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| congestive heart failure |
| hypertension |
| hypertensive disorder |
Australia Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 13378D | Dapa-Tabs | Tablet containing indapamide hemihydrate | Valid |
Safety Considerations
The data compiled for this report did not include label-based warnings or contraindications. Please refer to the TGA-approved Product Information (PI) for these.
- Conditions linked to indapamide as contraindications in a knowledge graph (not label text): liver disease, gallbladder disease, potassium deficiency, diabetes mellitus, diabetic ketoacidosis, hyperuricaemia, hyperparathyroidism, osteitis fibrosa, anuria and gout.
- Drug interactions: 100 interactions were identified. The first 20 reviewed are mostly Moderate, with a few Minor. Notable moderate interactions include:
- Antidiabetic agents: acarbose, alogliptin, albiglutide and metformin.
- Corticosteroids: hydrocortisone, dexamethasone, betamethasone, triamcinolone and beclomethasone.
- Amphotericin B (including the lipid complex).
- Others: bupropion, morphine, omeprazole, rabeprazole, cholecalciferol and bisacodyl.
- Minor interactions: doxycycline, hyoscyamine and atropine.
- Safety signals in the linked literature: overdose can cause prolonged hypotension, marked diuresis and hypokalaemia (PMID 19623566). Indapamide-associated choroidal effusion and acute angle-closure glaucoma have been reported (PMID 34736431), which argues against repurposing for glaucoma without further safety work.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.